Physician profile
Roopa Achuri
NPI 1225531635
$9,816.48
in general payments reported to CMS, 2019-2025
34 companies · $3,209 in 2025
The $3,209 reported for 2025 was more than what 97% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $265 · 2022: $1,111 · 2023: $2,246 · 2024: $2,985 · 2025: $3,209.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,283 · Education: $157.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,283.36 |
| Education | $156.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,769.77 | 2021-2025 | Enbrel, Evenity, Tavneos |
| Janssen Biotech, INC. | $1,052.28 | 2021-2025 | Tremfya, Simponi Aria, Remicade |
| Glaxosmithkline, LLC. | $1,045.94 | 2021-2025 | Benlysta |
| Abbvie INC. | $841.02 | 2021-2025 | Rinvoq |
| Pfizer INC. | $669.98 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $660.52 | 2022-2025 | |
| Radius Health, INC. | $438.58 | 2021-2025 | Tymlos |
| Ucb, INC. | $399.91 | 2023-2025 | Bimzelx, Cimzia |
| Lilly USA, LLC | $388.56 | 2021-2024 | Taltz |
| Astrazeneca Pharmaceuticals LP | $292.74 | 2022-2025 | Saphnelo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $291.88 | 2023-2025 | Ofev, Cyltezo |
| Aurinia Pharma U.S., INC. | $249.38 | 2021-2025 | Lupkynis |
| E.R. Squibb & Sons, L.L.C. | $193.78 | 2022-2025 | Orencia |
| Organon LLC | $190.25 | 2022-2025 | Hadlima, Renflexis |
| Ani Pharmaceuticals, INC. | $138.30 | 2023-2025 | Purified Cortrophin Gel |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $127.75 | 2023-2025 | |
| Sandoz INC. | $127.37 | 2023-2025 | Hyrimoz |
| Alexion Pharmaceuticals, INC. | $125.19 | 2023-2025 | Strensiq |
| Fresenius Kabi USA, LLC | $124.96 | 2023-2025 | Idacio |
| Horizon Therapeutics Plc | $120.49 | 2022-2023 | Krystexxa |
| Genentech USA, INC. | $86.21 | 2023-2024 | Actemra |
| Tersera Therapeutics LLC | $59.55 | 2025 | Quzyttir |
| Mallinckrodt Hospital Products INC. | $58.27 | 2025 | Acthar |
| Pharming Healthcare, INC. | $57.77 | 2022-2023 | Ruconest |
| Bioventus LLC | $54.34 | 2024 | Durolane |
| Octapharma USA, INC. | $42.77 | 2025 | Octagam Immune Globulin (Human) |
| Depuy Synthes Sales INC. | $42.27 | 2025 | Orthovisc |
| Fidia Pharma USA INC. | $37.47 | 2023-2025 | Hymovis |
| Invivyd INC | $23.30 | 2025 | Pemgarda |
| Ferring Pharmaceuticals INC. | $23.28 | 2023 | Euflexxa |
| Tonix Medicines, INC. | $22.93 | 2025 | Tonmya |
| Ultragenyx Pharmaceutical INC. | $22.68 | 2023 | |
| Kyowa Kirin, INC. | $21.99 | 2024 | Crysvita |
| Kiniksa Pharmaceuticals, LTD. | $15.00 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Roopa Achuri listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.